SOURCE: Paragon Financial Limited

Paragon Financial Limited

November 16, 2011 08:16 ET

Positron Corporation and Boston Scientific Present Promising Growth Strategies

The Paragon Report Provides Equity Research on Positron Corporation & Boston Scientific

NEW YORK, NY--(Marketwire - Nov 16, 2011) - With profit margins for medical equipment and supply manufacturers already being squeezed via sweeping healthcare reform, companies in the sector could face more headwinds in the future as industry experts have begun questioning the FDAs approval process. The Paragon Report examines investing opportunities in the Medical Equipment & Supplies industry and provides equity research on Positron Corporation (OTCBB: POSC) and Boston Scientific Corporation (NYSE: BSX). Access to the full company reports can be found at:

www.paragonreport.com/POSC
www.paragonreport.com/BSX

Over the summer, The Institute of Medicine recommended that the US government create a new system of approving medical devices because the current system does not guarantee the products are safe. The panel from the Institute for Medicines also said the FDA should abandon a process that allows for medical devices to be approved if the manufacturers prove they are similar to devices that are already on the market. Currently, the FDA approves medical devices without human studies if it is "substantially equivalent" to other devices that were previously cleared or that were on the market before 1975.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the Medical Equipment & Supplies industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

The FDA says it disagrees with the recommendations and wants to amend its current process, not overhaul it. The current oversight system has been simultaneously faulted for inadequate assurance of safety and efficacy and for suppressing innovation. Since regulatory approval is dependent on claims of similarity to previously approved devices, the process can encourage the development of devices that provide only small improvements at higher cost than their predecessors.

Positron Corporation operates as a molecular imaging company providing nuclear medicine technologies and services that are used in the field of nuclear cardiology. Last week Positron and Manhattan Isotope Technology LLC. (MIT LLC) entered into a binding Letter of Intent to acquire MIT LLC. Manhattan Isotope is the leading commercial resource in the United States with practical knowledge and experience in all stages of strontium-82 production.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. It offers implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; and implantable pacemaker systems used to manage slow or irregular heart rhythms. Last week the company announced positive outcomes from its COBRA clinical trial, which evaluated post-dilation of nitinol stents using CryoPlasty Therapy with the PolarCath Peripheral Dilatation System compared to stenting with conventional balloon angioplasty in patients with diabetes presenting with blockages of the superficial femoral artery (SFA).

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer